The induction of 2F5-and 4E10-like antibodies broadly neutralising HIV-1 and targeting the membrane external proximal region (MPER) of the transmembrane envelope protein gp41 would be a major advancement for the development of a preventive HIV-1 vaccine but successful attempts remain rare. Recent studies demonstrated that broadly reactive antibodies develop relatively late during infection and after intensive affinity maturation. Therefore, a prolonged antigen delivery might be beneficial to induce them. Replicating foamy viruses which are characterised by apathogenic but persistent infection could represent suitable carrier viruses for this purpose. In order to develop such a system, we modified the accessory foamy virus Bet protein to contain the MPER of gp41, or the MPER linked to the stabilising fusion peptide proximal region (FPPR) of gp41 and analysed here the antigenic and immunogenic properties of such hybrid proteins. The antigens, expressed and purified to homogeneity, were recognised by the monoclonal antibodies 2F5 and 4E10 with nanomolar affinities and induced high levels of antibodies specific for gp41 after immunisation of rats. The antisera also bound to virus particles attached to infected cells and peptide-based epitope mapping showed that they recognised the 2F5 epitope. Although no HIV-1 neutralising activity was observed, the presented data demonstrate that using the foamy virus Bet for HIV-1 epitope delivery is successfully applicable. Together with the attractive potential for sustained antigen expression after transfer to replicating virus, these results should therefore provide a first basis for the development of chimeric foamy viruses as novel HIV-1 vaccine vectors.
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Immunisation with foamy virus Bet fusion proteins as novel strategy for HIV-1 epitope delivery
INTRODUCTION
For HIV-1 vaccine development, induction of broadly neutralising antibodies (bnAb) is the most promising approach to prevent infection and to avoid integration of the provirus into the genome of the target cell where it may persist [1, 2] . The viral envelope proteins composed of the surface and transmembrane (TM) subunits are the main target of neutralising antibodies and several potent bnAb directed against each subunit have been isolated from infected patients (reviewed in [3, 2] ). Most of these antibodies show unique properties such as a high degree of somatic mutation, prolonged CDR3 loops and polyreactivity and occur in about 20% of infected individuals only after about 4 years of infection [4] [5] [6] [7] . The findings suggest that these antibodies may arise from rare B-cell stimulation events or after intensive affinity maturation [8, 1, 6] , which is only partly achieved by repeated antigen administration [9] . Given that various attempts to induce bnAb completely failed or resulted in low-titred neutralising antibody responses with limited breadth [2] alternative approaches should be explored. Replicating viral vectors and attenuated vaccines have been found to be the most effective way to prevent infection in the non-human primate model [10] [11] [12] [13] and permit long-term antigen delivery by simultaneously stimulating strong cellular immune responses [10] . However, most of the replicating systems available to date raise safety concerns that limit/exclude their application in humans [14] . Foamy viruses (FV) are apathogenic viruses of the Spumaviriniae subfamily which are characterised through persistent infection, preferential integration sites, genetic stability and wide tissue tropism [15] [16] [17] [18] , favouring their application for gene therapy and vaccine purposes [19] [20] [21] [22] . Similarly, the feline foamy virus (FFV) was used as convenient model for the application in cats [23] [24] [25] [26] . In order to develop a vector system that could be tested in small animals and encouraged by previous immunisation studies with an antigen of the feline calicivirus [25] , a strategy for HIV-1 epitope delivery using the accessory FFV Bet protein was evaluated here. Bet is particularly useful as carrier antigen as it is highly expressed in infected cells resulting in a strong antibody response in infected animals [27] [28] [29] and it was reported to be secreted and taken up by adjacent cells [30, 31] , permitting the presentation of proteasome-unprocessed conformational epitopes to immune cells. As HIV-1 antigen, the membrane proximal external region (MPER) of the TM protein gp41 of HIV was selected to be appended to the FFV Bet protein. This domain is targeted by three bnAb, 2F5, Z13 and 4E10, and is therefore of particular interest as vaccine target [32] [33] [34] [35] . However, MPER-based vaccine development is complicated by the structural flexibility of the MPER required to promote membrane fusion and uncertainty about the conformation able to induce bnAb [36] [37] [38] [39] [40] [41] . Furthermore, the necessity for a lipid environment for induction of MPER directed bnAb is still under intensive investigation [42, 43] . In structural analyses, the 2F5-bound epitope ELDKWA forms a slightly distorted type 1 β-turn compared with an α-helical structure when the MPER is analysed alone [37, 44, 39] . Importantly, 2F5 also shows a higher affinity to antigens fixing its epitope as a β-turn compared to an α-helix, indicating that this conformation might resemble the initial B-cell trigger [45] [46] [47] [48] . In contrast, the bnAb 4E10 recognises the adjacent α-helical core sequence NWFN/DIT in the MPER and its affinity is enhanced when the antigens support α-helical structures [49] [50] [51] . Recent investigations supported an interaction of the MPER with the fusion peptide proximal region (FPPR) of gp41 and also showed that peptides corresponding to the FPPR increased binding of 2F5 to its epitope [52] [53] [54] [55] . This was attributed to a FPPR-induced orientation of MPER residues coinciding with an increased level of β-turn/β-sheet conformation [56, 57] . In order to use its constraining property, an additional antigen containing the FPPR and the MPER was included here. With the objective to evaluate bnAb binding to such novel Bet/HIV-1 gp41 hybrids before transfer to replicating FFV and to study the epitope specificity of antibodies obtained in response to vaccination, recombinant fusion proteins of the FFV Bet protein and the MPER and FPPR sequences of gp41 of HIV-1 were produced in this study, characterised and the antibody response in immunised rats was studied.
MATERIAL AND METHODS
Expression plasmids
To clone pQE-Bet and pQE-Bet/HIV-1 constructs, the complete FFV Bet sequence (Uniprot ID O93036) with additional four amino acids (AGAA) was amplified from the plasmid pBC12-Bet with the primers FFV Bet-fwd (5'-atggcttcaaaatacccggaagaaggacca-3') and FFV Bet-rev (5'-tcatctgactctgaagctggt-gcagccggctag-3') containing a NaeI site and introduced into the StuI and BamHI linearised prokaryotic expression vector pQE-30-Xa (Qiagen, Hilden, Germany). The constructs pQE-BetE1, pQE-BetE2 and pQE-BetE1-E2 were obtained by subcloning E1, E2 or E1-E2 sequences ( Fig. 1A ) with additional N-terminal linker amino acids (SGSAGAGAGGG) from two synthetic plasmids (GeneArt, Regensburg, Germany) which were introduced into the NaeI/HindIII digested pQE-Bet vector. All constructs were verified by sequencing.
Protein purification
After optimisation in 96 deep well plates [58], proteins were expressed in Escherichia coli SCS-1 bacteria (Agilent Technologies, Austin, USA) using 2YT medium, 37°C and 1 mM IPTG. For lysis, bacterial pellets were resuspended in PBS containing 0.1 mg/ml lysozyme, incubated on ice for 15 min and then sonicated for 3 x 20 s. Inclusion bodies were collected by centrifugation (10.000 g, 20 min) and resuspended in buffer A (100 mM NaH 2 PO 4 , 10 mM TrisHCl, 6 M GuHCl, 300 mM NaCl, 10 mM imidazole, pH 8.0). After centrifugation 2 h later (25.000 g, 20 min, 4°C), the supernatant was loaded onto a HisTrap Ni-NTA column (GE Healthcare, Munich, Germany), washed with buffer B (100 mM NaH 2 PO 4 , 10 mM TrisHCl, 8 M urea, 300 mM NaCl, 10 mM imidazole, pH 8.0) and bound proteins released using buffer C (100 mM NaH 2 PO 4 , 10 mM TrisHCl, 8 M urea, 300 mM NaCl, 500 mM imidazole, pH 8.0). Eluted fractions (2 mg/ml) were incubated with 20 mM β-mercaptoethanol for at least 3 h and renatured by 1:20 dilution in refolding buffer (50 mM HEPES, 300 mM NaCl, 100 mM Larginine, pH 9.0) for 24 h at room temperature followed by dialysis overnight against phosphate buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, pH 8.0). Proteins were concentrated by another Ni-NTA chromatography step using imidazolesupplied phosphate buffers.
ELISA and serum titration
ELISA plates (Greiner Bio-One, Frickenhausen, Germany) were coated with 100 ng/well of Bet/HIV-1 antigens, or 200 ng/well of purified gp41 (Uniprot ID P04578, amino acids 532-681) expressed in bacteria or synthetic HIV peptides (E1: AAGSTMGAASMTLTVQARLLLS-KKKK, E2: KKKKEQELLELDKWA-SLWNWFNITNWL, GeneCust, Dudelange, Luxembourg) and then blocked for 1 h at 37°C with 5% BSA in PBS/0.05% Tween (PBS-T). For each serum a tenfold dilution in 2.5% BSA with PBS-T was prepared in triplicates and plates were then incubated with the samples for 1 h at 37°C. After washing and addition of a peroxidase (HRP) coupled anti-rat IgG-HRP antibody (Dako, Hamburg, Germany, 1:3000) plates were developed with OPD (o-phenylendiamine dichloride) and read at 492 nm. For calculation of endpoint titres, the absorbance measured for immune sera at every dilution was plotted against the dilution step and data were fitted by a logarithmic regression function. 
Surface plasmon resonance (SPR)
SPR measurements were performed on a Biacore X100 device with anti-human IgG-Fc specific antibodies immobilised on CM5 chips (all GE Healthcare, Munich, Germany). 2F5 or 4E10 in 50 mM NaH 2 PO 4 , 300 mM NaCl, pH 8.0 were captured at 300-500 response units (RU) on flow cell 2 and three increasing concentrations of fusion proteins diluted in 50 mM NaH 2 PO 4 , 300 mM NaCl, pH 8.0 were injected on both flow cells. After regeneration with 10 mM glycine, pH 2.0, and antibody recapturing, blank resonance was measured by three injections of dilution buffer. Sensograms were reference cell subtracted and blank normalised values from at least two repeated experiments. Curves were fitted using the 1:1 Langmuir algorithm and quality of fitting was checked by assuring K D values in the range of measured protein concentrations, plausible R max values, small 2 values as well as residuals within recommended borders.
Immunisation
Wistar rats (Charles River, Wilmington, USA) in groups of four were immunised three times at intervals of three weeks with 250 μg of each antigen. 1 ml of protein emulsified in Freund's adjuvant were injected either subcutaneously (s.c) at four sites of the animal for the first injection or s.c. (4x 200 μl) and intramuscularly (2x 100 μl) for the second and third injection. Blood was taken by retrobulbar bleeding before immunisation (pre-immune sera, PI), two days before boost injections and three weeks after the last boost (serum 1, 2 and 3, respectively). All manipulations were in accordance with regular animal welfare guidelines and approved by the Landesamt für Gesundheit und Soziales, Berlin, Germany.
Epitope mapping
Epitope mapping was performed with PepStar peptide microarrays (JPT, Berlin, Germany) spotted with 15 mer peptides (12 residues overlap) of the extended HIV-1 HXB2 FPPR domain (amino acids 512-559) and the extended MPER domain (amino acids 644-691) as well as rat IgG as internal control. Sera were incubated on the array using a 24 multi-well hybridisation chamber (ArrayIt, Sunnyvale, USA) following the protocol recommended by JPT. Bound antibodies were detected using a DyLight 649 conjugated AffiniPure goat anti-rat IgG antibody (Jackson Immuno Research Labs, West Grove, USA, 1:500) and read at 635 nm in a GenePix 4000 microarray scanner (Molecular Devices, Sunnyvale, USA). Epitopes were defined as central amino acids shared by overlapping peptides with signal intensities above a 5000 RLU threshold. 
Flow cytometry and immunofluorescence
Neutralisation assay
TZM-bl cells (1 x 10 4 /well) were seeded in a 96 well cell culture plate. The next day, antisera were diluted 1:25 with medium and 50 μl of the dilution were incubated with 50 μl of 200 infectious units of titrated HIV-1 pNL4.3 for 30 min at 37°C and then added to the cells. As controls, non-infected, infected, and cells incubated with virus and 2F5 were used. Infection was analysed after 48 h by staining the cells with X-Gal solution (5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 , 2 mM MgCl 2 , 1 mg/ml X-Gal in PBS) and ELISPOT counting as described previously [60] . Neutralisation was defined as 50% reduction of stained cells when immune sera and pre-immune sera were compared.
RESULTS
Antigen design, production and purification
To add HIV-1 gp41 sequences to the bet sequence of FFV, a Bet expression vector was constructed in which the FPPR-derived E1 sequence, the MPERderived E2 sequence or both E1 and E2 sequences connected by a loop sequence were subsequently introduced to the C-terminus (Fig. 1a, b) . Between Bet and the corresponding HIV-1 parts, a flexible 15 amino acid glycine-serine-rich linker was introduced with the intention that HIV-1 epitopes protrude from the fusion partner and are thus more accessible for antibodies and immune cells. The E1-E2 loop construct used here was derived from the previously described alpha-turnalpha peptide [61] , which promotes the interaction of the alpha helical parts as a coiled coil [62] . Replacing the original alpha helices by HIV-1 FPPR and MPER domains except for eight amino acids flanking both termini of the loop, the construct was designed to mimic a form of gp41, where MPER and FPPR are in close proximity [63] . Additionally, both domains were connected with an amino acid spacing that allows interaction of contacting residues as found in the crystal structure of gp41 [38] . This construct was optimised and validated by secondary structure prediction algorithms and α-helical wheel projections to fit the desired criteria (Online Resource 1). Then, all three fusion proteins and Bet alone were produced in E. coli, purified by affinity chromatography and refolded by rapid dilution with typical yields of 11-18 mg/L expression culture. Characterisation of the antigens by SDS-PAGE showed their purity which usually exceeded 90% as judged by densitometric scanning of Coomassie stained gels (Fig. 1c) .
Recognition of the produced antigens by 2F5 and 4E10
To examine their reactivity with 2F5 and 4E10, antigens were first analysed in a Western blot assay. 2F5 and to a weaker extent also 4E10 reacted with all antigens containing the MPER epitopes but not with the unmodified Bet or the Bet-E1 protein (Fig. 1d) . Conversely, an epitope-mapped rat antiserum specific for the HIV-1 gp41 FPPR (recognising the epitope 541-TLTVQARQL-570) reacted with all E1-containing proteins but not with the Bet-E2 antigen (Fig. 1d ). Since denatured gp41 was generally better recognised by 2F5 and worse by 4E10 when compared to soluble gp41 [64], binding to non-denatured proteins was investigated in parallel ( Fig. 2 ). In the case of 2F5 minor differences in binding to the different E2-hybrid antigens were observed, with a reduced binding to the Bet-E1-E2 protein (Fig. 2) . In contrast, 4E10 bound strongly to the Bet-E1-E2 loop antigen, but poorly to the Bet-E2 or the combination of the Bet-E1 and Bet-E2 proteins and as expected not to Bet-E1 (Fig. 2) . These results demonstrated that all hybrid antigens properly displayed the corresponding HIV-1 domain(s) and that the presence of the E1 domain was beneficial for the presentation of the 4E10 but not the 2F5 epitope.
SPR analysis of 2F5 and 4E10 binding to the produced antigens
To study the binding of 2F5 and 4E10 to the hybrid proteins in more detail, SPR experiments were performed (Table 1, Online Resource 2). 2F5 binding to antigens containing the MPER alone or in combination with the FPPR domain was detectable down to the nanomolar range (K D = 4.8, 5.9 and 19 nM for Bet-E2, Bet-E1+Bet-E2 and Bet-E1-E2, respectively) whereas no interaction was observed for the Bet-E1 control construct (Table 1 , Online Resource 2). As above, no increase in binding was measured when a mixture of Bet-E2 and Bet-E1 was tested. Also, the affinity of 2F5 to the loop antigen was lower compared to Bet-E2 due to a twofold slower association and dissociation rate (Table 1 ). In line with the weaker Western blot and ELISA reactivity of 4E10, much higher fusion protein concentrations were needed in the SPR studies. Due to the precipitation of recombinant Bet/HIV-1 proteins above 1 mg/ml (corresponding to 15-20 μM) no suitable concentration ranges to obtain reliable data for the Bet-E2 antigen and the combination of Bet-E2 and Bet-E1 could be selected. At the highest concentration tested (8 μM), no binding of Bet-E1 and a weak signal (15 RU) for Bet-E2 was observed suggesting that the K D values of Bet-E2 were probably in the micromolar range (data not shown). However, when Bet-E1-E2 was analysed, kinetic constants could be determined, since nanomolar protein concentrations yielded stable data ( Table 1 ). The dissociation constant of 223 nM resulted from slow target recognition (k on =2.08x10 3 M −1 s −1 ) and a moderate dissociation rate (k off =4.66 x10 -4 , Table 1 ). Thus, the SPR data substantiated the ELISA results and the beneficial effect of the FPPR residues for enhanced 4E10 antibody binding.
Immunogenicity of fusion proteins
After validation of their antigenicity, rats were immunised with the fusion proteins. All animals showed a strong immune response to the administered antigens with antibody titres of 10 4 -10 6 already after the first immunisation ( Fig.  3 , Online Resource 3). The response peaked after the second injection and then remained at this level or slightly decreased, with no significant differences between the groups (Kruskal-Wallis, p = 0.262, p = 0.243 and p = 0.385 for first, second, and third immunisation, respectively). To study the immune response against the introduced HIV-derived E1 and E2 domains and to analyse whether these antibodies are also able to bind to gp41 of HIV-1, ELISA were performed using synthetic E1 and E2 peptides as well as purified recombinant gp41 produced in bacteria. All sera recognised the HIV-1 peptides as well as gp41 with titres ranging from 10 2 up to 10 5 (Fig. 4 , Online Resource 4). Notably, the reaction against the E1 domain (mean titre 10 5 ) was significantly stronger than that against the E2 domain (mean titer 10
3 ) in groups immunised with Bet-E1 and Bet-E2 antigen (Welch-t-test p = 0.027, Fig. 4a and b ). This was also true for sera from animals immunised with a mixture of both hybrid antigens (p = 0.0238) but did not reach significance in case of the hybrid E1-E2 loop antigen (p = 0.1565, Fig.  4c and d) . Among all, animals immunised with the Bet-E2 protein alone developed the strongest antibody response against the E2 peptide with mean titres up to 8 x 10 3 (p = 0.1274 and 0.0729 for comparisons to groups 366 and 375, respectively), followed by animals immunised with the mixture of Bet-E1 plus Bet-E2 (p = 0.0809 for group 375, Fig. 4b and b, Online Resource 4). The antibody response against recombinant gp41 correlated well with that against each individual domain (Fig. 4a-d) and was confirmed by Western blot analysis (Online Resource 5). Taken together, these results demonstrated that all antigens used were highly immunogenic and that HIV-1 specific antibodies were induced.
Epitope mapping of the antisera
By mapping sera using overlapping peptides corresponding to the FPPR and MPER, distinct epitopes were identified (Fig. 5) . As shown by two representative mappings, all rats immunised with the Bet-E1 hybrid antigen developed a strong response against the E1 domain with the epitope TLTVQARQL. Administration of the Bet-E2 hybrid antigen to rats resulted in antibodies recognising the epitopes ELLELDKWA or ELLELDKWASLW overlapping with the 2F5 epitope (underlined). Sera from animals immunised with a mixture of the E1 and E2 hybrid protein showed a predominant response to the E1 epitope TLTVQARQL and a rather weak response to the E2 epitope NEQELLELDKWASLW. When sera from animals treated with the Bet-E1-E2 loop antigen were investigated, the main response was directed against the E1 epitope TLTVQARQL, but the E2 response was variable, with one serum reacting with NEQELLELDKWA whereas no MPER reactivity was observed in case of a second animal (Fig. 5) . These results were consistent with the prior ELISA titration experiments and confirmed the overall lower E2 reactivity observed before. In terms of consistency and strength in which 2F5 epitope-specific antibodies were induced, the Bet-E2 antigen appeared to be superior to all other antigens.
Binding of induced antibodies to infected cells
Since prior analysis of antibody binding was mainly based on shorter fragments of the full length Env, the binding of antisera to native protein as presented on the surface of infected cells should be also investigated. Therefore, C8166 cells were infected with HIV-1 and binding of antisera from animals with strong antibody titres along with a pre-immune rat serum as control were analysed by flow cytometry and indirect immunofluorescence (Fig. 6) . Neglectable binding was observed with the control serum, but sera from immunised animals showed profound fluorescence ranging from moderate to strong dependent on the immunised antigen (Fig. 6a) . Recognition of infected cells by the serum from group 364 (Bet E1) was rather weak (28.7%), however, rat sera from groups 365, 366 and 375 reacted intensely with 65.9, 55.5 and 57.9%, respectively. In indirect immunofluorescence analysis, the same sera gave signals with varying appearance. Antisera of rats 364, containing only FPPR directed antibodies (Fig.  4, Fig. 5 ) caused rather weak and diffuse staining with no clear pattern. In contrast, all antisera that contained E2 directed antibodies (rats 365, 366, 375) gave spot-like signals distributed on the surface of the cells, most probably showing antibodies binding to the produced or infecting virus (Fig. 6b) . This observation was in line with the finding that the gp41 MPER is most accessible in a fusion intermediate state after attachment of gp120 to its cellular receptors [65, 66] . Thus, at least antisera with MPER specificity seemed to be able to react with native Env as mandatory for virus neutralisation.
Analysis of neutralising activity
Although some of the immunised animals developed antibodies binding to epitopes overlapping with the 2F5 epitope and bound to virus particles, all sera did not prevent HIV-1 infection in a TZM-bl indicator cell line-based neutralisation assay when used at dilutions of 1:50 (Online Resource 6). 2F5 was effectively inhibiting infection.
DISCUSSION
In the present study a novel strategy for HIV-1 epitope delivery based on FFVBet/HIV-gp41 fusion proteins containing the epitopes of the bnAb 2F5 and 4E10 was evaluated. Milligram amounts of these proteins as needed for immunisation and antigen characterisation were produced in E. coli, purified to homogeneity and renatured to obtain soluble molecules. The antigens specifically reacted with 2F5, 4E10 and a serum against the E1 domain and were immunogenic in rats generating antibodies targeting an epitope overlapping with the 2F5 epitope; however, they did not prevent HIV-1 infection in a TZM-bl based neutralisation assay. The antigens comprised the HIV-1 MPER-derived E2 domain because the corresponding bnAb antibodies are characterised by strong somatic mutations which could benefit from prolonged antigen delivery by replicating vectors [67] . Additionally, some Bet hybrids contained the FPPR derived E1 domain and the E2 domain linked by a loop to stabilise a MPER conformation that increases 2F5 binding [56, 53, 57, 54] . Introducing the MPER domain alone resulted in high affinity recognition by 2F5, with values comparable to or better than previously reported for MPER peptides or MPER epitope scaffolds [68, 47, 69] . Unexpectedly, the affinity of 2F5 to its epitope decreased to some extent when the FPPR residues were present ( Table 1 ). This suggests that the selected positioning of the FPPR residues might not allow proper orientation of the 2F5 epitope or formation of the affinity enhancing β-turn structure and might result from a divergence between the bioinformatic predictions used to design this antigen and the actual structure. However, by stepwise optimisation of the FPPR and MPER epitope presentation with an extended set of loop antigens, enhanced antigenicity of 2F5 was observed in later experiments (Mühle et al, in preparation) . In contrast to 2F5, the FPPR residues remarkably improved 4E10 binding (Fig. 2, Table 1 ). Crystallisation experiments with 2F5-Fab have shown that the presence of FPPR residues not only stabilised the β-turn structure of the 2F5 epitope but also induced the formation of α-helices in the adjacent C-terminal residues [56] . Such an increase in α-helical content might explain the higher affinity of 4E10 to the loop construct used here, since enhanced binding for 4E10 to α-helical peptides has been reported [50] . However, the affinity of 4E10 to the loop antigen was still weak when compared to 2F5 (223 nM compared to 19 nM, Table 1 ) or previous antigens designed for induction of 4E10-like antibodies [49, 50] and potentially explains the 2F5 epitope-dominated response observed (Fig. 5) . For improvement, the E2 domain may be extended by at least three additional amino acids (YIK) to increase the affinity for 4E10 [49, 50] . When used as protein immunogen, Bet was found to be an effective carrier molecule for the small HIV-1 epitopes, triggering a profound humoral response to the introduced inserts (Fig. 4, Online Resource 4) . Importantly, antibodies targeting ELDKWA and binding to gp41 and virions were induced, particularly with the Bet-E2 antigen which also showed the highest affinity to 2F5 and the strongest antibody response against the MPER (Table 1, Fig. 4) . Despite the high titres of binding antibodies, none of the immune sera were neutralising, indicating that high affinity and immunogenicity do not predict the ability of antigens to induce antibodies capable to prevent HIV-1 infection as was found also by others [68, 47, 70, 48] . It is difficult to judge whether the antigens used here did not provide a conformation able to induce neutralising antibodies or whether their amount in the antibody population was too low to be detected. To further increase MPER-specific responses, certain mutations that have been recently described to enhance its immunogenicity could be beneficial [71] . Also, in order to avoid the FPPR-dominated responses observed here when the E1 domain was present, introduction of a glycosylation site into the FPPR might be considered to immunologically silence the E1 reactivity and focus the immune system to the MPER region [72] . As the antisera were binding to virus particles (Fig. 6 ) but were not neutralising, one could speculate that the induced antibodies lack certain characteristics like (i) lipid binding, which is not promoted by the strategy used here, or (ii) prolonged CDRH3 loops, which could arise as a result of somatic mutation after extended B-cell stimulation. Whereas the first point will have to be tested with other strategies, e.g. by placing the HIV-1 MPER epitope into the TM protein of FV, the second question could be addressed by extended antigen delivery. This might be achieved in part by extended boosting as shown for a recombinant gp120 antigen inducing a limited degree of affinity maturation [9] or more efficiently by using replicating FV vectors which permanently express the antigen. Thus, after showing the general feasibility of using Bet/HIV-1 fusion proteins for induction of HIV-1 MPER specific antibodies, optimised hybrid proteins should now be expressed in replication-competent virus and the expression of the HIV epitopes monitored in infected eukaryotic cells. These replication-competent viruses may first be used in cats in order to analyse whether prolonged and systemic delivery of such proteins induce not only antibodies binding to epitopes overlapping with the 2F5 epitope, but also antibodies neutralising HIV-1. If successful, this would justify transfer to primate FV and testing in non-human primates. Recognition of the produced antigens by the monoclonal antibodies 2F5 and 4E10 and a FPPR specific antiserum. 150 ng of recombinant proteins were transferred onto a PVDF membrane and tested with the antibodies 2F5 (0.4 μg/ml), 4E10 (1.2 μg/ml) and an E1 specific rat serum (1:800) to confirm the presence of the corresponding HIV-1 domains Fig. 2 Recognition of the produced antigens by the monoclonal antibodies 2F5 and 4E10 under non-denaturing conditions in an ELISA. 100 ng of indicated Bet/HIV-1 antigens in phosphate buffer were coated and incubated with 2F5 (11.3 μg/μl) or 4E10 (11.9 μg/μl) serially diluted as indicated, followed by detection with an HRP anti-human IgG antibody and developed with OPD. Whereas only minor differences of 2F5 binding were detected, threefold increased binding of 4E10 to the FPPR stabilised Bet-E1-E2 protein was found . The endpoint titers of (a) sera from rat group 364, (b) sera from rat group 365, (c, d) sera from rat groups 366 and 375, all titrated against the E1 and/or E2 peptides as well as recombinant gp41, are given. The administered antigen is indicated in brackets Online Resource 3 Western blot analysis of antisera of the final bleeding using purified recombinant gp41 as antigen (200 ng gp41/lane). Antisera (1:1000) were incubated on the membrane using a slot blot chamber and an anti-rat HRP-labelled secondary antibody for detection. The number of the animals is indicated. 2F5 was used as positive control (113 ng/ml) Online Resource 4 Neutralisation assays based on TZM-bl cells and titrated HIV-pNL-4.3. Virus was incubated for 30 min at 37°C with either 2F5 (25, 12.5, 6.25 and 3.12 μg/ml, positive control), pre-immune sera (PI) or immune sera (1:50) of the indicated animal group (364-375), animal number (#1-4) and bleeding and then added to TZM-bl cells plated one day in advance. 48 h after assay setup, cells were stained for infection with X-gal and colonies counted using an ELISPOTreader. Neutralisation was defined as 50% reduction of stained cells when immune sera and preimmune sera were compared. Whereas 2F5 was effectively neutralising, none of the immune sera achieved reduction of viral infection by more than 50% 
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